Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1 H-pyrido[4,3-b ]indol-5(2 H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 4899-4911

  Fretz, Heinz ^a   Valdenaire, Anja ^a   Pothier, Julien ^a   Hilpert, Kurt ^a   Gnerre, Carmela ^a   Peter, Oliver ^a   Leroy, Xavier ^a   Riederer, Markus A ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 ( 2 BENZOYL 3,4 DIHYDRO 1H PYRIDO[4,3 B]INDOL 5 (2H) YL)ACETIC ACID; ANTIALLERGIC AGENT; INDOMETACIN; RAMATROBAN; SETIPIPRANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; STRUCTURE ACTIVITY RELATION; TRAFFIC; TRAFFIC LIGHT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; INDOLES; MALE; NAPHTHALENES; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84879587293     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400122f     Document Type: Article

References (40)

1. Papadopoulos, N. G.; Agache, I.; Bavbek, S.; Bilo, B. M.; Braido, F.; Cardona, V.; Custovic, A.; Demonchy, J.; Demoly, P.; Eigenmann, P.; Gayraud, J.; Grattan, C.; Heffler, E.; Hellings, P. W.; Jutel, M.; Knol, E.; Lotvall, J.; Muraro, A.; Poulsen, L. K.; Roberts, G.; Schmid-Grendelmeier, P.; Skevaki, C.; Triggiani, M.; Vanree, R.; Werfel, T.; Flood, B.; Palkonen, S.; Savli, R.; Allegri, P.; Annesi-Maesano, I.; Annunziato, F.; Antolin-Amerigo, D.; Apfelbacher, C.; Blanca, M.; Bogacka, E.; Bonadonna, P.; Bonini, M.; Boyman, O.; Brockow, K.; Burney, P.; Buters, J.; Butiene, I.; Calderon, M.; Cardell, L. O.; Caubet, J. C.; Celenk, S.; Cichocka-Jarosz, E.; Cingi, C.; Couto, M.; Dejong, N.; Del Giacco, S.; Douladiris, N.; Fassio, F.; Fauquert, J. L.; Fernandez, J.; Rivas, M. F.; Ferrer, M.; Flohr, C.; Gardner, J.; Genuneit, J.; Gevaert, P.; Groblewska, A.; Hamelmann, E.; Hoffmann, H. J.; Hoffmann-Sommergruber, K.; Hovhannisyan, L.; Hox, V.; Jahnsen, F. L.; Kalayci, O.; Kalpaklioglu, A. F.; Kleine-Tebbe, J.; Konstantinou, G.; Kurowski, M.; Lau, S.; Lauener, R.; Lauerma, A.; Logan, K.; Magnan, A.; Makowska, J.; Makrinioti, H.; Mangina, P.; Manole, F.; Mari, A.; Mazon, A.; Mills, C.; Mingomataj, E.; Niggemann, B.; Nilsson, G.; Ollert, M.; O'Mahony, L.; O'Neil, S.; Pala, G.; Papi, A.; Passalacqua, G.; Perkin, M.; Pfaar, O.; Pitsios, C.; Quirce, S.; Raap, U.; Raulf-Heimsoth, M.; Rhyner, C.; Robson-Ansley, P.; Alves, R. R.; Roje, Z.; Rondon, C.; Rudzeviciene, O.; Rueff, F.; Rukhadze, M.; Rumi, G.; Sackesen, C.; Santos, A. F.; Santucci, A.; Scharf, C.; Schmidt-Weber, C.; Schnyder, B.; Schwarze, J.; Senna, G.; Sergejeva, S.; Seys, S.; Siracusa, A.; Skypala, I.; Sokolowska, M.; Spertini, F.; Spiewak, R.; Sprikkelman, A.; Sturm, G.; Swoboda, I.; Terreehorst, I.; Toskala, E.; Traidl-Hoffmann, C.; Venter, C.; Vlieg-Boerstra, B.; Whitacker, P.; Worm, M.; Xepapadaki, P.; Akdis, C. A. Research needs in allergy: an EAACI position paper, in collaboration with EFA Clin. Transl. Allergy 2012, 2 (21) 1-23
2. Barnes, P. J. New drugs for asthma Semin. Respir. Crit. Care Med. 2012, 33, 685-694
3. Quirce, S.; Bobolea, I.; Barranco, P. Emerging drugs for asthma Expert. Opin. Emerging Drugs 2012, 17, 219-237
4. Peters, S. P.; Schleimer, R. P.; Kagey-Sobotka, A.; Naclerio, R. M.; MacGlashan, D. W., Jr.; Schulman, E. S.; Adkinson, N. F., Jr.; Lichtenstein, L. M. The role of prostaglandin D2 in IgE-mediated reactions in man Trans. Assoc. Am. Physicians 1982, 95, 221-228
5. Lewis, R. A.; Soter, N. A.; Diamond, P. T.; Austen, K. F.; Oates, J. A.; Roberts, L. J., 2nd. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE J. Immunol. 1982, 129, 1627-1631
6. Crea, A. E.; Nakhosteen, J. A.; Lee, T. H. Mediator concentrations in bronchoalveolar lavage fluid of patients with mild asymptomatic bronchial asthma Eur. Respir. J. 1992, 5, 190-195
7. Liu, M. C.; Bleecker, E. R.; Lichtenstein, L. M.; Kagey-Sobotka, A.; Niv, Y.; McLemore, T. L.; Permutt, S.; Proud, D.; Hubbard, W. C. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma Am. Rev. Respir. Dis. 1990, 142, 126-132
8. Hirai, H.; Tanaka, K.; Yoshie, O.; Ogawa, K.; Kenmotsu, K.; Takamori, Y.; Ichimasa, M.; Sugamura, K.; Nakamura, M.; Takano, S.; Nagata, K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J. Exp. Med. 2001, 193, 255-261
9. Mjosberg, J. M.; Trifari, S.; Crellin, N. K.; Peters, C. P.; van Drunen, C. M.; Piet, B.; Fokkens, W. J.; Cupedo, T.; Spits, H. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161 Nat. Immunol. 2011, 12, 1055-1062
10. Xue, L.; Gyles, S. L.; Wettey, F. R.; Gazi, L.; Townsend, E.; Hunter, M. G.; Pettipher, R. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells J. Immunol. 2005, 175, 6531-6536
11. Yoshimura-Uchiyama, C.; Iikura, M.; Yamaguchi, M.; Nagase, H.; Ishii, A.; Matsushima, K.; Yamamoto, K.; Shichijo, M.; Bacon, K. B.; Hirai, K. Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2 Clin. Exp. Allergy 2004, 34, 1283-1290
12. Tanaka, K.; Hirai, H.; Takano, S.; Nakamura, M.; Nagata, K. Effects of prostaglandin D2 on helper T cell functions Biochem. Biophys. Res. Commun. 2004, 316, 1009-1014
13. Wills-Karp, M.; Luyimbazi, J.; Xu, X.; Schofield, B.; Neben, T. Y.; Karp, C. L.; Donaldson, D. D. Interleukin-13: central mediator of allergic asthma Science 1998, 282, 2258-2261
14. Grunig, G.; Warnock, M.; Wakil, A. E.; Venkayya, R.; Brombacher, F.; Rennick, D. M.; Sheppard, D.; Mohrs, M.; Donaldson, D. D.; Locksley, R. M.; Corry, D. B. Requirement for IL-13 independently of IL-4 in experimental asthma Science 1998, 282, 2261-2263
15. Matsuoka, T.; Hirata, M.; Tanaka, H.; Takahashi, Y.; Murata, T.; Kabashima, K.; Sugimoto, Y.; Kobayashi, T.; Ushikubi, F.; Aze, Y.; Eguchi, N.; Urade, Y.; Yoshida, N.; Kimura, K.; Mizoguchi, A.; Honda, Y.; Nagai, H.; Narumiya, S. Prostaglandin D2 as a mediator of allergic asthma Science 2000, 287, 2013-2017
16. Kostenis, E.; Ulven, T. Emerging roles of DP and CRTH2 in allergic inflammation Trends Mol. Med. 2006, 12, 148-158
17. Hart, F. D.; Boardman, P. L. Indomethacin: a new non-steroid anti-inflammatory agent Br. Med. J. 1963, 2, 965-970
18. Hirai, H.; Tanaka, K.; Takano, S.; Ichimasa, M.; Nakamura, M.; Nagata, K. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2 J. Immunol. 2002, 168, 981-985
19. Rosentreter, U.; Boshagen, H.; Seuter, F.; Perzborn, E.; Fiedler, V. B. Synthesis and absolute configuration of the new thromboxane antagonist (3 R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer Arzneim. Forsch. 1989, 39, 1519-1521
20. Aizawa, H.; Shigyo, M.; Nogami, H.; Hirose, T.; Hara, N. BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics Chest 1996, 109, 338-342
21. Terada, N.; Yamakoshi, T.; Hasegawa, M.; Tanikawa, H.; Maesako, K.; Ishikawa, K.; Konno, A. The effect of ramatroban (BAY u 3405), a thromboxane A2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis Acta Otolaryngol. Suppl. 1998, 537, 32-37
22. Sugimoto, H.; Shichijo, M.; Iino, T.; Manabe, Y.; Watanabe, A.; Shimazaki, M.; Gantner, F.; Bacon, K. B. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro J. Pharmacol. Exp. Ther. 2003, 305, 347-352
23. Pettipher, R.; Whittaker, M. Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis J. Med. Chem. 2012, 55, 2915-2931
24. Valdenaire, A.; Pothier, J.; Renneberg, D.; Riederer, M. A.; Peter, O.; Leroy, X.; Gnerre, C.; Fretz, H. Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1 H -indol-3-yl)acrylamide scaffold Bioorg. Med. Chem. Lett. 2013, 23, 944-948
25. Boie, Y.; Sawyer, N.; Slipetz, D. M.; Metters, K. M.; Abramovitz, M. Molecular cloning and characterization of the human prostanoid DP receptor J. Biol. Chem. 1995, 270, 18910-18916
26. Stubbs, V. E.; Schratl, P.; Hartnell, A.; Williams, T. J.; Peskar, B. A.; Heinemann, A.; Sabroe, I. Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils J. Biol. Chem. 2002, 277, 26012-26020
27. Sabroe, I.; Hartnell, A.; Jopling, L. A.; Bel, S.; Ponath, P. D.; Pease, J. E.; Collins, P. D.; Williams, T. J. Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways J. Immunol. 1999, 162, 2946-2955
28. Fretz, H.; Fecher, A.; Hilpert, K.; Riederer, M. A. Preparation of Tetrahydropyridoindole Derivatives as CRTH2 Receptor Antagonists for the Treatment of Prostaglandin-Mediated Diseases PCT Int. Appl. WO 2005095397 A1 20051013, 2005.
29. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
30. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249
31. Asafu-Adjaye, E. B.; Faustino, P. J.; Tawakkul, M. A.; Anderson, L. W.; Yu, L. X.; Kwon, H.; Volpe, D. A. Validation and application of a stability-indicating HPLC method for the in vitro determination of gastric and intestinal stability of venlafaxine J. Pharm. Biomed. Anal. 2007, 43, 1854-1859
32. Lobell, M.; Hendrix, M.; Hinzen, B.; Keldenich, J.; Meier, H.; Schmeck, C.; Schohe-Loop, R.; Wunberg, T.; Hillisch, A. In silico ADMET traffic lights as a tool for the prioritization of HTS hits ChemMedChem 2006, 1, 1229-1236
33. Tanimoto, N.; Hiramatsu, Y.; Mitsumori, S.; Inagaki, M., Preparation of Indole Derivatives as PGD2 Receptor Antagonists. PCT Int. Appl. WO 2003097598 A1 20031127, 2003.
34. Ruediger, E. H.; Deon, D., H.; Kadow, J. F. Preparation of Tetrahydrocarbolines for Treatment of HIV Infection and AIDS. U.S. Pat. Appl. Publ. US 20050267130 A1 20051201, 2005.
35. Bonjoch, J.; Diaba, F.; Pages, L.; Perez, D.; Soca, L.; Miralpeix, M.; Vilella, D.; Anton, P.; Puig, C. Synthesis and structure-activity relationships of gamma-carboline derivatives as potent and selective cysLT(1) antagonists Bioorg. Med. Chem. Lett. 2009, 19, 4299-4302
36. Ivashchenko, A. A.; Ivashchenko, A. V.; Tkachenko, S. Y.; Okun, I. M.; Savchuk, N. F.; Mitkin, O. D.; Kravchenko, D. V. Substituted 2,3,4,5-Tetrahydro-1 H -pyrido[4,3- b ]indoles as Novel Antihistaminic Agents and Processes for Preparation Thereof. PCT Int. Appl. WO 2008115098 A2 20080925, 2008.
37. Ivashchenko, A. V.; Mit'kin, O. D.; Kisil, V. M.; Frolov, E. B.; Tkachenko, S. E. Izv. Vyssh. Uchebn. Zaved., Khim. Khim. Tekhnol. 2009, 52, 78-83
38. Shimizu, T.; Yamashita, A.; Hayaishi, O. Specific binding of prostaglandin D2 to rat brain synaptic membrane. Occurrence, properties, and distribution J. Biol. Chem. 1982, 257, 13570-13575
39. Fortini, A.; Modesti, P. A.; Abbate, R.; Gensini, G. F.; Neri Serneri, G. G. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets Thromb. Res. 1985, 40, 319-328
40. Sawyer, N.; Cauchon, E.; Chateauneuf, A.; Cruz, R. P.; Nicholson, D. W.; Metters, K. M.; O'Neill, G. P.; Gervais, F. G. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2 Br. J. Pharmacol. 2002, 137, 1163-1172